{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancer+Metastatic&page=12", "query": { "condition": "Gastrointestinal Cancer Metastatic", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 2359, "total_pages": 236, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancer+Metastatic&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancer+Metastatic&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T14:06:37.602Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003557", "title": "Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Liver Cancer" ], "interventions": [ { "name": "dolastatin 10", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "1999-01", "completion_date": "2003-08", "has_results": false, "last_update_posted_date": "2014-03-06", "last_synced_at": "2026-11-15T14:06:37.602Z", "location_count": 11, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 6 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003557" }, { "nct_id": "NCT02568267", "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Cholangiocarcinoma", "Colorectal Cancer", "Head and Neck Neoplasms", "Lymphoma, Large-Cell, Anaplastic", "Melanoma", "Neuroendocrine Tumors", "Non-Small Cell Lung Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Papillary Thyroid Cancer", "Primary Brain Tumors", "Renal Cell Carcinoma", "Sarcomas", "Salivary Gland Cancers", "Adult Solid Tumor" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 534, "start_date": "2015-11-19", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-11-15T14:06:37.602Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02568267" }, { "nct_id": "NCT00005607", "title": "Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "FOLFIRI regimen", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Robert H. Lurie Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-19", "last_synced_at": "2026-11-15T14:06:37.602Z", "location_count": 4, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005607" }, { "nct_id": "NCT00844649", "title": "Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Albumin-bound paclitaxel (ABI-007)", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 861, "start_date": "2009-03-01", "completion_date": "2013-04-09", "has_results": true, "last_update_posted_date": "2019-11-25", "last_synced_at": "2026-11-15T14:06:37.602Z", "location_count": 90, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 71 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00844649" }, { "nct_id": "NCT02570711", "title": "Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "ACP-196", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2015-10-13", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-11-15T14:06:37.602Z", "location_count": 10, "location_summary": "Ventura, California • Fort Myers, Florida • Durham, North Carolina + 6 more", "locations": [ { "city": "Ventura", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02570711" }, { "nct_id": "NCT01498952", "title": "MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unresectable or Metastatic Hepatocellular Carcinoma (HCC)" ], "interventions": [ { "name": "MEDI-573 (1 of 3 doses)", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 6, "start_date": "2012-01-17", "completion_date": "2013-04-09", "has_results": true, "last_update_posted_date": "2019-02-19", "last_synced_at": "2026-11-15T14:06:37.602Z", "location_count": 3, "location_summary": "Oxnard, California • Golden Springs, Colorado • Las Vegas, Nevada", "locations": [ { "city": "Oxnard", "state": "California" }, { "city": "Golden Springs", "state": "Colorado" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT01498952" }, { "nct_id": "NCT00220649", "title": "Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Neoplasms" ], "interventions": [ { "name": "gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Luke's-Roosevelt Hospital Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2004-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-08-17", "last_synced_at": "2026-11-15T14:06:37.602Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00220649" }, { "nct_id": "NCT00031616", "title": "NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "brivudine phosphoramidate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NewBiotics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-11-15T14:06:37.602Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031616" }, { "nct_id": "NCT00088933", "title": "Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extensive Stage Small Cell Lung Cancer", "Recurrent Colon Cancer", "Recurrent Non-small Cell Lung Cancer", "Recurrent Rectal Cancer", "Recurrent Small Cell Lung Cancer", "Stage IV Colon Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage IV Rectal Cancer" ], "interventions": [ { "name": "recombinant fowlpox-CEA(6D)/TRICOM vaccine", "type": "DRUG" }, { "name": "recombinant vaccinia-CEA(6D)-TRICOM vaccine", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "sargramostim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2004-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-03-31", "last_synced_at": "2026-11-15T14:06:37.602Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00088933" }, { "nct_id": "NCT06625515", "title": "First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Breast Cancer Recurrent", "Colorectal Cancer Metastatic", "Colon Cancer", "Rectal Adenocarcinoma", "Endometrial Cancer" ], "interventions": [ { "name": "ATX-559", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accent Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2024-10-11", "completion_date": "2026-01-09", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-11-15T14:06:37.602Z", "location_count": 5, "location_summary": "Aurora, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625515" } ] }